Correlation Between Leap Therapeutics and Cellectis

Can any of the company-specific risk be diversified away by investing in both Leap Therapeutics and Cellectis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Leap Therapeutics and Cellectis into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Leap Therapeutics and Cellectis SA, you can compare the effects of market volatilities on Leap Therapeutics and Cellectis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Leap Therapeutics with a short position of Cellectis. Check out your portfolio center. Please also check ongoing floating volatility patterns of Leap Therapeutics and Cellectis.

Diversification Opportunities for Leap Therapeutics and Cellectis

0.72

Correlation Coefficient

Leap Therapeutics  Cellectis

Poor diversification

The 3 months correlation between Leap and Cellectis is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Leap Therapeutics and Cellectis SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cellectis SA and Leap Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Leap Therapeutics are associated (or correlated) with Cellectis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cellectis SA has no effect on the direction of Leap Therapeutics i.e., Leap Therapeutics and Cellectis go up and down completely randomly.

Pair Corralation between Leap Therapeutics and Cellectis

Given the investment horizon of 90 days Leap Therapeutics is expected to under-perform the Cellectis. In addition to that, Leap Therapeutics is 2.2 times more volatile than Cellectis SA. It trades about -0.24 of its total potential returns per unit of risk. Cellectis SA is currently generating about -0.1 per unit of volatility. If you would invest  182.00  in Cellectis SA on December 29, 2024 and sell it today you would lose (55.00) from holding Cellectis SA or give up 30.22% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Leap Therapeutics  vs.  Cellectis SA

Leap Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Leap Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Cellectis SA

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cellectis SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Leap Therapeutics and Cellectis

The main advantage of trading using opposite Leap Therapeutics and Cellectis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Leap Therapeutics position performs unexpectedly, Cellectis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cellectis will offset losses from the drop in Cellectis' long position.

The idea behind Leap Therapeutics and Cellectis SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.